Lung cancer: New biological insights and recent therapeutic advances
SS Ramalingam, TK Owonikoko… - CA: a cancer journal for …, 2011 - Wiley Online Library
Approximately 1.6 million new cases of lung cancer are diagnosed each year throughout the
world. In many countries, the mortality related to lung cancer continues to rise. The outcomes …
world. In many countries, the mortality related to lung cancer continues to rise. The outcomes …
Treatment of non–small-cell lung cancer with erlotinib or gefitinib
VD Cataldo, DL Gibbons, R Pérez-Soler… - … England Journal of …, 2011 - Mass Medical Soc
Treatment of Non–Small-Cell Lung Cancer with Erlotinib or Gefitinib | New England Journal of
Medicine Skip to main content The New England Journal of Medicine homepage Advanced …
Medicine Skip to main content The New England Journal of Medicine homepage Advanced …
Biomarker analyses and final overall survival results from a phase III, randomized, open-label, first-line study of gefitinib versus carboplatin/paclitaxel in clinically …
M Fukuoka, YL Wu, S Thongprasert… - Journal of clinical …, 2011 - ascopubs.org
Purpose The results of the Iressa Pan-Asia Study (IPASS), which compared gefitinib and
carboplatin/paclitaxel in previously untreated never-smokers and light ex-smokers with …
carboplatin/paclitaxel in previously untreated never-smokers and light ex-smokers with …
Disease Flare after Tyrosine Kinase Inhibitor Discontinuation in Patients with EGFR-Mutant Lung Cancer and Acquired Resistance to Erlotinib or Gefitinib …
Purpose: Treatment of patients with oncogene-addicted cancers with tyrosine kinase
inhibitors (TKI) is biologically and clinically different than with cytotoxic chemotherapy. We …
inhibitors (TKI) is biologically and clinically different than with cytotoxic chemotherapy. We …
EGFR nuclear translocation modulates DNA repair following cisplatin and ionizing radiation treatment
Epidermal growth factor receptor (EGFR) overexpression is associated with resistance to
chemotherapy and radiotherapy. It modulates DNA repair after radiation-induced damage …
chemotherapy and radiotherapy. It modulates DNA repair after radiation-induced damage …
Phase III trial of vandetanib compared with erlotinib in patients with previously treated advanced non–small-cell lung cancer
RB Natale, S Thongprasert, FA Greco… - Journal of Clinical …, 2011 - ascopubs.org
Purpose Vandetanib is a once-daily oral inhibitor of vascular endothelial growth factor
receptor and epidermal growth factor receptor signaling. This phase III study assessed the …
receptor and epidermal growth factor receptor signaling. This phase III study assessed the …
Vandetanib plus pemetrexed for the second-line treatment of advanced non–small-cell lung cancer: a randomized, double-blind phase III trial
RH De Boer, Ó Arrieta, CH Yang, M Gottfried… - Journal of Clinical …, 2011 - ascopubs.org
Purpose Vandetanib is a once-daily oral inhibitor of vascular endothelial growth factor
receptor and epidermal growth factor receptor signaling. This randomized, placebo …
receptor and epidermal growth factor receptor signaling. This randomized, placebo …
KRAS and BRAF: drug targets and predictive biomarkers
Three decades have passed since RAS was first identified as the transformative factor in the
Harvey and Kirsten strains of the mouse sarcoma virus. RAS and several of its downstream …
Harvey and Kirsten strains of the mouse sarcoma virus. RAS and several of its downstream …
Gefitinib as first-line treatment for patients with advanced non-small-cell lung cancer with activating epidermal growth factor receptor mutation: Review of the evidence
C Gridelli, F De Marinis, M Di Maio, D Cortinovis… - Lung Cancer, 2011 - Elsevier
Gefitinib is a small molecule tyrosine kinase inhibitor of epidermal growth factor receptor
(EGFR). Since 2004, it was clear that a substantial proportion of non-small-cell lung cancers …
(EGFR). Since 2004, it was clear that a substantial proportion of non-small-cell lung cancers …
Phase II evaluation of gefitinib in patients with newly diagnosed Grade 4 astrocytoma: Mayo/North Central Cancer Treatment Group Study N0074
JH Uhm, KV Ballman, W Wu, C Giannini… - International Journal of …, 2011 - Elsevier
PURPOSE: Amplification of the epidermal growth factor receptor (EGFR) gene represents
one of the most frequent gene alterations in glioblastoma (GBM). In the current study, we …
one of the most frequent gene alterations in glioblastoma (GBM). In the current study, we …